Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610462 | 0.90 | LMNA (0.35) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL10188806 | 0.81 | PTGS2 (0.35) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL9951558 | 0.77 | HTR2A (0.35) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL9951554 | 0.77 | HTR2A (0.35) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL13720499 | 0.76 | TSHR (0.40) | LMNACYP2D6 | |
| SCHEMBL4022057 | 0.76 | TSHR (0.40) | LMNACYP2D6 | |
| SCHEMBL13045928 | 0.75 | KCNH2 (0.39) | MAOBMAOA | |
| SCHEMBL20747663 | 0.72 | PTGS2 (0.41) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL21834929 | 0.72 | PTGS2 (0.41) | PTGS2MAOBHTR2CHTR2AHTR2B | |
| SCHEMBL16638921 | 0.72 | SLC6A2 (0.31) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | PTGS2 1465/4885MAOB 546/4885HTR2C 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.